アリイズミ シユンイチ
Ariizumi Shiyun'ichi
有泉 俊一 所属 医学部 医学科(東京女子医科大学病院) 職種 准教授 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読なし |
表題 | Intrahepatic cholangiocarcinoma. |
掲載誌名 | 正式名:Seminars in diagnostic pathology 略 称:Semin Diagn Pathol ISSNコード:(0740-2570)0740-2570(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 34(2),pp.160-166 |
著者・共著者 | NAKANO Masayuki†*, ARIIZUMI Shunichi, YAMAMOTO Msakazu |
担当区分 | 2nd著者 |
発行年月 | 2017/03 |
概要 | Cholangiocarcinoma, also referred to as cholangiocellular carcinoma (particularly in Japan), develops along the biliary tract. The tumor may be intra- or extrahepatic and have different features with specific treatments based on the site of origin. Guidelines for diagnosis and management of cholangiorcarcinoma, such as those proposed by EASL (European Association for the Study of the Liver)1 and the Mayo Clinic2 classify the tumor into intrahepatic, perihilar, and distal cholangiocarcinoma. There are three main macroscopic patterns of growth of cholangiocarcinoma: mass-forming, periductal-infiltrating and intraductal. A combination of mass-forming and periductal infiltrating tumors have been shown to have a poor prognosis.3 Intrahepatic cholangiocarcinoma (ICC) comprises two microscopic subtypes: bile duct and cholangiolar.4 The bile duct subtype has tall columnar cells that form large glands, whereas cholangiolar tumors are composed of cuboidal and low columnar cells. Patients with cholangiolar tumors, referred to as cholangiolocellular carcinoma, reportedly have a better 5-year survival rate than those with the bile duct type.4. |
DOI | 10.1053/j.semdp.2016.12.012 |
PMID | 28094162 |